Maunsell Farris Maryanne

VP, Chief Accounting Officer

Haemonetics Corporation

US, Boston [HQ]

CIK 1950052

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

557

Price per Share :

$73.49

Equivalence :

$40,933.93

F

Form 4

557 Shares After Transaction

Value : $53,744.93

$7,043.77

Transaction Date : 05/15/24
- Footnotes
- Form 4
Footnotes:
#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

#2 This number includes unvested RSUs previously reported.
A

Form 4

1,144 Shares After Transaction

Value : $n/a

$0.0

Transaction Date : 05/17/24
- Footnotes
- Form 4
Footnotes:
#1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

#2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

#3 This number includes unvested RSUs previously reported.

NYSE

United States

Boston

Healthcare

Medical Instruments & Supplies